Endo International (Endo International) Interest Expense : $-1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Endo International Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Endo International's interest expense for the three months ended in Dec. 2023 was $ -0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Endo International's Operating Income for the three months ended in Dec. 2023 was $ 80 Mil. Endo International's Interest Expense for the three months ended in Dec. 2023 was $ -0 Mil. Endo International's Interest Coverage for the quarter that ended in Dec. 2023 was 313.49. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Endo International Interest Expense Historical Data

The historical data trend for Endo International's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo International Interest Expense Chart

Endo International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-538.73

-532.94

-562.35

-350.74

-0.99

Endo International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.80	-0.26	-0.27	-0.20	-0.25

Endo International Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1 Mil.

Endo International (OTCPK:ENDPQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Endo International's Interest Expense for the three months ended in Dec. 2023 was $-0 Mil. Its Operating Income for the three months ended in Dec. 2023 was $80 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $4 Mil.

Endo International's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	79.626	/	-0.254
	=	313.49

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Endo International PLC has enough cash to cover all of its debt. Its financial situation is stable.

Endo International (Endo International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

EO7:Germany

Address

Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4

Website

https://www.endo.com

Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.

Executives

James Patrick Tursi	officer: Executive VP, Global R&D	106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti	officer: VP, Controller and CAO	C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke	director	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague	director
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol	officer: EVP, Head of Global R&D	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith	director	3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley	officer: EVP, Chief Financial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio	director	19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle	officer: SVP, Interim Controller	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel	director	LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico	officer: EVP & Chief Commercial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella	officer: EVP, Intl Pharmaceuticals	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol	officer: VP, Controller & CAO	927 GRANDVIEW DRIVE, EXTON PA 19341